PT - JOURNAL ARTICLE AU - Hamamsy, Tymor AU - Bonneau, Richard TI - Twitter activity about treatments during the COVID-19 pandemic: case studies of remdesivir, hydroxychloroquine, and convalescent plasma AID - 10.1101/2020.06.18.20134668 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.18.20134668 4099 - http://medrxiv.org/content/early/2020/07/14/2020.06.18.20134668.short 4100 - http://medrxiv.org/content/early/2020/07/14/2020.06.18.20134668.full AB - Since the COVID-19 pandemic started, the public has been eager for news about promising treatments, and social media has played a large role in information dissemination. In this paper, our objectives are to characterize the public discussion of treatments on Twitter, and demonstrate the utility of these discussions for public health surveillance. We pulled tweets related to three promising COVID-19 treatments (hydroxychloroquine, remdesivir and convalescent plasma), between the dates of February 28th and May 22nd using the Twitter public API. We characterize treatment tweet trends over this time period. Most major tweet/retweet/sentiment trends correlated to public announcement made by the white house and/or to new clinical trial evidence about treatments. Most of the websites people shared in treatment-related tweets were non-scientific, ideological media sources that leaned conservative. Hydroxychloroquine was the most discussed treatment on Twitter. There is a gap between the public attention/discussion around COVID-19 treatments and their evidence. Twitter data can and should be used for public health surveillance during this pandemic, as it is informative for monitoring adverse drug reactions, especially as many people avoid going to hospitals/doctors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementRB and TH acknowledge support from the following sources: NIH R01DK103358, Simons Foundation, NSF- IOS-1546218, R35GM122515, NSF CBET- 1728858, NIH R01AI130945.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethical approval was needed for this cohort study that uses publicly accessible Twitter data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be shared upon request. Due to the terms and conditions of Twitter, we can only share the tweet ids of tweets, and not the tweet text.